OCUL Ocular Therapeutix

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024.

Presentation & Panel Details (all times CT):

Eyecelerator® @ AAO 2024: October 17

  • Panel Title: Fueling Progress: The Power of Innovation and Perseverance

    Session: S3

    Panel Date/Time: Thursday, October 17, 10:00 – 11:00 AM

    Ocular Therapeutix Panelist: Pravin U. Dugel, MD, Executive Chair, President and CEO
  • Company Presentation: Ocular Therapeutix: Transformation Into A Retina-focused Company

    Session: Eyecelerator @ AAO 2024 Retina Showcase, Room E450a

    Presentation Date/Time: Thursday, October 17, 1:24 – 1:31 PM

    Presenter: Peter K. Kaiser, MD, Chief Development Officer

Innovate RETINA 2024: October 17

  • Panel Title: The Future of Retinal Therapeutics

    Session: Session 5

    Panel Date/Time: Thursday, October 17, 6:30 PM

    Ocular Therapeutix Panelist: Pravin U. Dugel, MD, Executive Chair, President and CEO

American Academy of Ophthalmology® (AAO 2024): October 18 -- 21, Chicago, Illinois

  • Poster Presentation: Fifty-Two-Week Sustained Efficacy and Treatment Burden Reduction with OTX-TKI in the U.S. Phase 1 Trial for nAMD

    Session: PO582, On Demand throughout the meeting

    Presenter: David A. Eichenbaum, MD, FASRS

A full copy of the poster will be available on the “Investors” page of the Ocular website under the "Scientific & Medical Presentations" tab.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations



EN
09/10/2024

Underlying

OCULOcular Therapeutix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

Free Trial
OCUL Ocular Therapeu...

Ocular Therapeutix Inc: 2 directors

Two Directors at Ocular Therapeutix Inc sold after exercising options/bought 63,739 shares at between 7.660USD and 7.740USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by ...

OCUL OCULAR THERAPEUTIX
02/25/26 February 25, 2026 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Participate in March Investor Conferences

Ocular Therapeutix™ to Participate in March Investor Conferences BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference:Date: Monday, March 2, 2026Fireside Chat: 9:10 – 9:40 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Jefferies Biotech on the Beach Summit:Dat...

February 24, 2026 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula ...

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experi...

February 23, 2026 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase...

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p

February 17, 2026 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superio...

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical ...

February 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch